Anti-interleukin-2 receptor monoclonal antibody Mikbeta1

Drug Profile

Anti-interleukin-2 receptor monoclonal antibody Mikbeta1

Alternative Names: Anti-CD122 monoclonal antibody Mikβ1; HuMikβ1-1; Interleukin-2 receptor beta monoclonal antibody Mikβ1; Mikβ1

Latest Information Update: 06 Aug 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer National Institutes of Health (USA); Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 06 Aug 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
  • 25 Mar 1996 New profile
  • 20 Mar 1996 Preclinical development for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top